| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 9 | CN 1 | 99.77 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 58 | CN 2 | 99.67 |
| Ferroptosis and cancer prognosis | Lifetime | 86 | CN 30 | 98.58 |
| Immune cells in cancer | Lifetime | 173 | CN 17 | 98.89 |
| Acute Ischemic Stroke Management | Lifetime | 283 | CN 9 | 99.11 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 144 | CN 8 | 98.71 |
| Kruppel-like factors research | Lifetime | 102 | CN 10 | 97.62 |
| Mesenchymal stem cell research | Lifetime | 442 | CN 50 | 97.84 |
| Heme Oxygenase-1 and Carbon Monoxide | Lifetime | 250 | CN 10 | 97.01 |
| Histone Deacetylase Inhibitors Research | Lifetime | 340 | CN 22 | 96.78 |
| Inflammasome and immune disorders | Lifetime | 376 | CN 31 | 96.45 |
| Neurosurgical Procedures and Complications | Lifetime | 368 | CN 8 | 96.73 |
| Neurogenesis and neuroplasticity mechanisms | Lifetime | 753 | CN 21 | 96.49 |
| Nerve injury and regeneration | Lifetime | 773 | CN 38 | 95.94 |
| Traditional Chinese Medicine Studies | Lifetime | 501 | CN 301 | 91.19 |
| S100 Proteins and Annexins | Lifetime | 848 | CN 19 | 93.37 |
| Nuclear Receptors and Signaling | Lifetime | 956 | CN 61 | 89.22 |
| Barrier Structure and Function Studies | Lifetime | 665 | CN 26 | 88.84 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 865 | CN 162 | 87.67 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 30 | CN 5 | 99.08 |
| S100 Proteins and Annexins | 2021-2025 | 7 | CN 1 | 97.59 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 23 | CN 4 | 98.74 |
| Acute Ischemic Stroke Management | 2021-2025 | 277 | CN 37 | 97.78 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 237 | CN 7 | 96.37 |
| Immune cells in cancer | 2021-2025 | 371 | CN 200 | 93.39 |
| Ferroptosis and cancer prognosis | 2021-2025 | 493 | CN 412 | 93.64 |
| MicroRNA in disease regulation | 2021-2025 | 659 | CN 399 | 93.33 |
| Mitochondrial Function and Pathology | 2021-2025 | 367 | CN 50 | 92.16 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 558 | CN 82 | 93.92 |
| Inflammasome and immune disorders | 2021-2025 | 314 | CN 158 | 90.66 |
| Alzheimer's disease research and treatments | 2021-2025 | 842 | CN 86 | 91.58 |
| Mesenchymal stem cell research | 2021-2025 | 502 | CN 161 | 87.50 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 317 | CN 129 | 85.44 |
| Cell Adhesion Molecules Research | 2021-2025 | 296 | CN 36 | 83.08 |
| Trace Elements in Health | 2021-2025 | 466 | CN 169 | 82.61 |
| Pain Mechanisms and Treatments | 2021-2025 | 743 | CN 146 | 83.78 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 255 | CN 107 | 80.20 |
| Immune Response and Inflammation | 2021-2025 | 794 | CN 320 | 77.30 |
| Barrier Structure and Function Studies | 2021-2025 | 254 | CN 50 | 73.22 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 966 | CN 210 | 67.23 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 570 | CN 188 | 64.50 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 750 | CN 180 | 62.28 |
| Ginger and Zingiberaceae research | 2021-2025 | 820 | CN 286 | 50.14 |
